Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement

Autor: Aytac, Erman, Ozer, Leyla, Baca, Bilgi, Balik, Emre, Kapran, Yersu, Taskin, Orhun Cig, Uluc, Basak Oyan, Abacioglu, Mehmet Ufuk, Gonenc, Murat, Bolukbasi, Yasemin, Cil, Barbaros E., Baran, Bulent, Aygun, Cem, Yildiz, Mehmet Erdem, Unal, Kemal, Erkol, Burcak, Yalti, Tunc, Ozbek, Ugur, Attila, Tan, Tozun, Nurdan, Gurses, Bengi, Erdamar, Sibel, Er, Ozlem, Bese, Nuran, Bilge, Orhan, Ceyhan, Guralp Onur, Mandel, Nil Molinas, Selek, Ugur, Yakicier, Cengiz, Karabey, Hulya Kayserili, Saruc, Murat, Ozben, Volkan, Esen, Eren, Ozoran, Emre, Vardareli, Erkan, Guner, Levent, Hamzaoglu, Ismail, Bugra, Dursun, Karahasanoglu, Tayfun, Grp, Istanbul

Publikováno v: The Turkish Journal of Gastroenterology. 33:627-663

Colorectal cancer is the third most common cancer in Turkey. The current guidelines do not provide sufficient information to cover all aspects of the management of rectal cancer. Although treatment has been standardized in terms of the basic principl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e3eb1f25b7c32518acfb11132260a3
https://doi.org/10.5152/tjg.2022.211103

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Autor: Seda Kahraman, Enes Erul, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Burcin Cakan Demirel, Omer Acar, Sercan Aksoy, Naziyet Kose Baytemur, Elif Sahin, Devrim Cabuk, Gul Basaran, Semra Paydas, Arzu Yaren, Deniz Can Guven, Atike Pinar Erdogan, Umut Demirci, Alper Yasar, İbrahim Vedat Bayoglu, Mutlu Hizal, Burcu Gulbagci, Nail Paksoy, Sena Ece Davarci, Funda Yilmaz, Ozlem Dogan, Sibel Oyucu Orhan, Erkan Kayikcioglu, Ali Aytac, Merve Keskinkilic, Eda Eylemer Mocan, Olcun Umit Unal, Esra Aydin, Hakan Yucel, Deniz Isik, Onder Eren, Basak Oyan Uluc, Melike Ozcelik, Ilhan Hacibekiroglu, Adnan Aydiner, Hacer Demir, Berna Oksuzoglu, Ebru Cilbir, Erdem Cubukcu, Bulent Cetin, Esin Oktay, Cihan Erol, Sadi Kerem Okutur, Nilgun Yildirim, Ali Alkan, Fatih Selcukbiricik, Asude Aksoy, Yusuf Karakas, Gulhan Ozkanli, Berna Bozkurt Duman, Dincer Aydin, Ozgecan Dulgar, Muhammed Muhiddin Er, Fatih Teker, Tugba Yavuzsen, Musa Baris Aykan, Ali Inal, Yakup Iriagac, Nurhan Onal Kalkan, Murat Keser, Teoman Sakalar, Serkan Menekse, Engin Kut, Burak Bilgin, Muge Karaoglanoglu, Veli Sunar, Ozlem Ozdemir, Nazim Serdar Turhal, Nuri Karadurmus, Bulent Yalcin, Mehmet Ali Nahit Sendur

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4603b0dea982cdc71feb0666817cb5
https://avesis.deu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

Autor: Özlem Özdemir, Baha Zengel, Yaşar Yildiz, Basak Oyan Uluç, Devrim Cabuk, Ercan Ozden, Derya Kivrak Salim, Semra Paydas, Atakan Demir, Omer Diker, Kezban Nur Pilanci, Özlem Uysal Sönmez, Sezai Vatansever, Izzet Dogan, Ahmet Gulmez, Burcu Cakar, Pinar Gursoy, Mahmut Emre Yildirim, Murat Ayhan, Nuri Karadurmus, Musa Baris Aykan, Gökcen Tugba Cevik, Teoman Sakalar, Ilhan Hacibekiroglu, Burcu Belen Gülbagci, Murat Dincer, Duygu Bayir Garbioglu, Yasemin Kemal, Erdinc Nayir, Halil Taskaynatan, Mesut Yilmaz, Okan Avci, Murat Sari, Ezgi Coban, Muhammed Mustafa Atci, Selin Aktürk Esen, Tugba Akin Telli, Fatih Karatas, Ali Inal, Hacer Demir, Nurhan Onal Kalkan, Cengiz Yilmaz, Funda Tasli, Ahmet Alacacioglu

In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::934c684ccacc5bd283fae448009bb29f
https://hdl.handle.net/11454/77368

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Autor: Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt

Publikováno v: BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)

Abstract Background The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival (OS) compared to placebo. In rea

Externí odkaz: https://doaj.org/article/7d19cca4236d429b8424cc6bef6070f5